Tonix Pharmaceuticals And Massachusetts General Hospital Enter Into Research Collaboration To Develop Tonix's Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, For The Treatment And Prevention Of Organ Transplant Rejection